11 research outputs found

    Optimization of the metabolic stability of a fluorinated cannabinoid receptor subtype 2 (CB2) ligand designed for PET studies

    Get PDF
    The central CB2 receptor represents a promising target for the treatment of neuroinflammatory diseases as CB2 activation mediates anti-inflammatory effects. Recently, the F-18 labeled PET radiotracer [F-18]7a was reported, which shows high CB2 affinity and high selectivity over the CB1 subtype but low metabolic stability due to hydrolysis of the amide group. Based on these findings twelve bioisosteres of 7a were synthesized containing a non-hydrolysable functional group instead of the amide group. The secondary amine 23a (K-i = 7.9 nM) and the ketone 26a (K-i = 8.6 nM) displayed high CB2 affinity and CB2:CB1 selectivity in in vitro radioligand binding studies. Incubation of 7a, 23a and 26a with mouse liver microsomes and LC-quadrupole-MS analysis revealed a slightly higher metabolic stability of secondary amine 23a, but a remarkably higher stability of ketone 26a in comparison to amide 7a. Furthermore, a logD(7.4) value of 5.56 +/- 0.08 was determined for ketone 26a by micro shake-flask method and LC-MS quantification. (C) 2018 Elsevier Masson SAS. All rights reserved.Medicinal Chemistr

    Scope and Trends of Volunteering and Associations

    Get PDF
    This chapter has two themes: (1) the scope of formal and informal volunteering and of nonprofit, voluntary, Membership Associations (MAs) in the world, by which we mean the quantitative magnitudes of these phenomena at or near the present time, and (2) the long term and recent (past few decades) trends in these magnitudes. Global data are used, when available, but we also report data for world regions and for specific nations when feasible. We also report on estimated magnitudes of MA wealth and income, the economic value of volunteering, internal structures and processes of MAs, participation rates in MAs, methodological problems, and issues regarding computer mapping of data such at that presented in this chapter. Usable knowledge, future trends, and needed research are discussed

    LUF7244, an allosteric modulator/activator of K v11.1 channels, counteracts dofetilide-induced torsades de pointes arrhythmia in the chronic atrioventricular block dog model

    No full text
    Background and Purpose: K v11.1 (hERG) channel blockade is an adverse effect of many drugs and lead compounds, associated with lethal cardiac arrhythmias. LUF7244 is a negative allosteric modulator/activator of K v11.1 channels that inhibits early afterdepolarizations in vitro. We tested LUF7244 for antiarrhythmic efficacy and potential proarrhythmia in a dog model. Experimental Approach: LUF7244 was tested in vitro for (a) increasing human I Kv11.1 and canine I Kr and (b) decreasing dofetilide-induced action potential lengthening and early afterdepolarizations in cardiomyocytes derived from human induced pluripotent stem cells and canine isolated ventricular cardiomyocytes. In vivo, LUF7244 was given intravenously to anaesthetized dogs in sinus rhythm or with chronic atrioventricular block. Key Results: LUF7244 (0.5–10 μM) concentration dependently increased I Kv11.1 by inhibiting inactivation. In vitro, LUF7244 (10 μM) had no effects on I KIR2.1, I Nav1.5, I Ca-L, and I Ks, doubled I Kr, shortened human and canine action potential duration by approximately 50%, and inhibited dofetilide-induced early afterdepolarizations. LUF7244 (2.5 mg·kg −1·15 min −1) in dogs with sinus rhythm was not proarrhythmic and shortened, non-significantly, repolarization parameters (QTc: −6.8%). In dogs with chronic atrioventricular block, LUF7244 prevented dofetilide-induced torsades de pointes arrhythmias in 5/7 animals without normalization of the QTc. Peak LUF7244 plasma levels were 1.75 ± 0.80 during sinus rhythm and 2.34 ± 1.57 μM after chronic atrioventricular block. Conclusions and Implications: LUF7244 counteracted dofetilide-induced early afterdepolarizations in vitro and torsades de pointes in vivo. Allosteric modulators/activators of K v11.1 channels might neutralize adverse cardiac effects of existing drugs and newly developed compounds that display QTc lengthening
    corecore